Medications Development for Stimulant Dependence 3 (MDS 3)

Notice Number: NOT-DA-08-023

RFP Available: N01DA-8-8878

Key Dates
Release Date:  January 8, 2008

Issued by
National Institute on Drug Abuse (NIDA), (http://www.nida.nih.gov )

The National Institute on Drug Abuse (NIDA) plans to solicit proposals from qualified investigational sites having the capability to conduct Phase I and/or Phase II and Phase III clinical trials of potential treatment medications, both investigational and marketed, for treatment of (1) stimulant abuse and dependence (i.e., cocaine, or methamphetamine), (2) codependence with alcohol and stimulants, (3) nicotine dependence and (4) marijuana abuse and dependence. Specifically, interested parties must be capable of conducting clinical trials to investigate the efficacy and safety of medications for the treatment of stimulant addiction, codependence with stimulants and alcohol, and nicotine under the current Food and Drug Administration regulations and ICH guidelines. NIDA will supply the study protocol and database management services. Those interested must be able to provide all other necessary services to conduct clinical trials.

In order to handle substances under the Controlled Substances Act of 1970, having or being able to obtain a DEA Research Registration for Schedules II to V and demonstrating the capability to obtain a DEA registration for Schedule I controlled substances will be mandatory.

RFP No. N01DA-8-8878 will be available electronically on or about January 18, 2008.  You will access the RFP through the FedBizOpps (URL: http://www.fedbizopps.gov) or through the NIDA website: (URL: http://www.nida.nih.gov/RFP/RFPList.html). All information required for the submission of a proposal is contained in or accessible through the RFP package. Response to the RFP will be due on or about  50 days after RFP release date.  NIDA will consider proposals submitted by any responsible offeror.  We anticipate the award of up to six cost reimbursement task order contracts for a period of five years.     NIDA will consider proposals submitted by any responsible offeror.     This advertisement does not commit the Government to award a contract.

Inquiries

Pedro M. Godinez, Contracting Specialist
National Institute on Drug Abuse, NIH
NIDA R&D Contracts Management Branch
6101 Executive Blvd., Room 260, MSC 8402
Bethesda, Maryland  20892-8402
E-mail: pgodinez@nida.nih.gov
Telephone: (301) 443-6677
Fax:  (301) 443-7595


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.